

# MEANING OF A POSITIVE RESULT

## CNS demyelinating diseases (AQP4 and MOG)

Aquaporin-4 (AQP4)-IgG and myelin oligodendrocyte glycoprotein (MOG)-IgG1 are not found in MS or healthy subjects, and detection of both antibodies in serum is rare and unusual.

### AQP4+

This result is consistent with an autoimmune astrocytopathy/NMOSD and justifies initiation of optimal immunosuppressive therapy at the earliest possible time. Follow-up in 3 to 6 months is recommended if NMOSD is suspected and initial testing is negative.

### MOG+

This result is consistent with an NMO-like phenotype, and in the setting of acute disseminated encephalomyelitis, optic neuritis, and transverse myelitis, it indicates an autoimmune oligodendrogliopathy with potential for relapsing course. Identification of MOG-IgG1 allows distinction from MS and may justify initiation of appropriate immunosuppressive therapy (not MS disease-modifying agents) at the earliest possible time. Follow-up in 6 to 12 months is recommended as persistence of MOG-IgG1 seropositivity predicts a relapsing course.



**MAYO CLINIC**  
Mayo Medical Laboratories

1-800-533-1710

Patient ID SA00100681	Patient Name TESTINGRW, CDS1	Birth Date 1986-09-25	Gender F	Age 31
Order Number SA00100681	Client Order Number SA00100681	Ordering Physician CLIENT, CLIENT		Report Notes
Account Information C7028846 DLMP Rochester		Collected 12 Nov 2017 00:00		

**CNS Demyelinating Disease Eval, S**

**CNS Demyelinating Disease Interp, S** MCR

This autoantibody supports the diagnosis of neuromyelitis optica or a neuromyelitis optica spectrum disorder. Neurological accompaniments include optic neuritis, myelitis and encephalitis. Seropositivity predicts high risk for relapse.

Result Name	Result	Unit	Reference Value	Performing Site
NMO/AQP4 FACS, S	See NMOTS Reflex		Negative	① MCR
<small>NMO/AQP4 FACS Titer reflexed. See NMOTS for final result.</small>				
MOG FACS, S	Negative		Negative	① MCR

Received: 13 Nov 2017 10:34

Reported: 13 Nov 2017 10:38

**NMO/AQP4 FACS Titer, S**

Result Name	Result	Unit	Reference Value	Performing Site
 NMO/AQP4 FACS Titer, S	Positive 1:100	titer	<1:5	① MCR

Received: 13 Nov 2017 10:34

Reported: 13 Nov 2017 11:19

**Laboratory Notes**

① This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

**Performing Site Legend**

Code	Laboratory	Address
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905

Printed 13 Nov 2017

**Report Status: Final**  
Received and reported dates and times are reported in US Central Time.

Page 1 of 1